Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Total Debt (2017 - 2025)

Aytu Biopharma (AYTU) has disclosed Total Debt for 14 consecutive years, with $11.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Debt changed 0.13% to $11.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.9 million, a 0.13% change, with the full-year FY2025 number at $12.8 million, down 3.92% from a year prior.
  • Total Debt was $11.9 million for Q4 2025 at Aytu Biopharma, down from $25.3 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $25.3 million in Q3 2025 to a low of $600000.0 in Q1 2021.
  • A 5-year average of $13.6 million and a median of $14.4 million in 2022 define the central range for Total Debt.
  • Peak YoY movement for Total Debt: crashed 96.55% in 2021, then skyrocketed 2277.83% in 2022.
  • Aytu Biopharma's Total Debt stood at $1.3 million in 2021, then skyrocketed by 1545.09% to $22.0 million in 2022, then crashed by 31.62% to $15.0 million in 2023, then dropped by 21.16% to $11.8 million in 2024, then grew by 0.13% to $11.9 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Total Debt are $11.9 million (Q4 2025), $25.3 million (Q3 2025), and $12.8 million (Q2 2025).